Core Insights - Phio Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing therapeutics using its proprietary INTASYL® siRNA gene silencing technology to combat cancer [1][4] - The company will present updates on its ongoing Phase 1b clinical trial for its lead product candidate PH-762 at the Life Sciences Future Conference on September 25-26, 2025 [1][2] Company Overview - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is advancing its INTASYL® gene silencing technology, particularly in the field of immuno-oncology [4] - The lead clinical program, PH-762, targets the PD-1 gene associated with various skin cancers, including cutaneous squamous cell carcinoma, melanoma, and Merkel cell carcinoma [4] - The ongoing Phase 1b trial (NCT 06014086) is evaluating PH-762 as a potential non-surgical treatment for skin cancers [4] Conference Details - The presentation by Mr. Robert Bitterman, President and CEO, will include updates on the Phase 1b clinical trial and future strategies for the PH-762 development program [2] - The Life Sciences Future Conference will take place at the Sheraton Valley Forge Hotel in King of Prussia, PA, on September 25-26, 2025 [3]

Core Viewpoint - iTeos Therapeutics, Inc. intends to wind down its operations as part of a strategic review aimed at maximizing shareholder value through potential asset sales and leveraging its cash balance [2][3]. Group 1: Company Operations - The Board of Directors has decided to cease clinical and operational activities following a comprehensive assessment of the company's development pipeline and financial position [3]. - The company is exploring potential asset sales, including EOS-984, EOS-215, and a preclinical obesity program targeting ENT1, to deliver near-term value to shareholders [2][3]. Group 2: Company Background - iTeos Therapeutics is a clinical-stage biopharmaceutical company focused on developing immuno-oncology therapeutics, leveraging its expertise in tumor immunology [4].